Autolus Therapeutics plc (NASDAQ: AUTL) open the trading on July 12, 2021, with a bit cautious approach as it glided -1.71% to $6.88. During the day, the stock rose to $7.0716 and sunk to $6.70 before settling in for the price of $7.00 at the close. Taking a more long-term approach, AUTL posted a 52-week range of $4.60-$17.19.The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 7.20%. Meanwhile, its Annual Earning per share during the time was -53.50%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 4.20%. This publicly-traded company’s shares outstanding now amounts to $62.45 million, simultaneously with a float of $33.90 million. The organization now has a market capitalization sitting at $455.39 million. At the time of writing, stock’s 50-day Moving Average stood at $6.52, while the 200-day Moving Average is $8.17.
Let’s gauge the efficiency of the firm, which has a total of 376 employees. It has generated 635 per worker during the last fiscal year. Meanwhile, its income per employee was -372,915. The stock had 0.01 Receivables turnover and 0.00 Total Asset turnover. For the Profitability, stocks operating margin was -70090.08 and Pretax Margin of -68701.24.
Autolus Therapeutics plc (AUTL) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Autolus Therapeutics plc’s current insider ownership accounts for 25.58%, in contrast to 31.80% institutional ownership.
Autolus Therapeutics plc (AUTL) Earnings and Revenue Records
This company achieved a net margin of -58716.53 while generating a return on equity of -61.61.
Autolus Therapeutics plc’s EPS increase for this current 12-month fiscal period is 4.20% and is forecasted to reach -1.92 in the upcoming year.
Autolus Therapeutics plc (NASDAQ: AUTL) Trading Performance Indicators
Let’s observe the current performance indicators for Autolus Therapeutics plc (AUTL). It’s Quick Ratio in the last reported quarter now stands at 9.40. The Stock has managed to achieve an average true range (ATR) of 0.47. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 284.62.
In the same vein, AUTL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.69, a figure that is expected to reach -0.50 in the next quarter, and analysts are predicting that it will be -1.92 at the market close of one year from today.
Technical Analysis of Autolus Therapeutics plc (AUTL)
[Autolus Therapeutics plc, AUTL] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 68.40% While, its Average True Range was 0.46.
Raw Stochastic average of Autolus Therapeutics plc (AUTL) in the period of the previous 100 days is set at 62.81%, which indicates a major fall in contrast to 63.55% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 49.28% that was lower than 83.69% volatility it exhibited in the past 100-days period.